

Shazia Afridi's publications

Afridi S, Kaube H. Prophylactic Therapy for Migraine. *Curr Treat Options Neurol* 2003 5:431-440.

Afridi S, Goadsby PJ. New onset migraine with a brainstem cavernous angioma. *J Neurol Neurosurg Psychiatry* 2003;74(5):680-682.

Afridi SK, Kaube H, Goadsby PJ. Glyceryl trinitrate triggers premonitory symptoms in migraineurs. *Pain* 2004 Aug;110(3):675-80

Afridi S, Bacon CM, Bowling J, Goadsby PJ. Verapamil and lymphomatoid papulosis in chronic cluster headache. *J Neurol* 2004;251(4):473-475

Afridi SK, Matharu MS, Lee L, Kaube H, Friston K, RSJ Frackowiak RSJ, Goadsby PJ. A PET study exploring the laterality of brainstem activation in migraine using glyceryl trinitrate. *Brain* 2005, 128:932-939

Afridi SK, Giffin N, Kaube H, Friston K, Ward N, Frackowiak RSJ, Goadsby PJ. A PET study in spontaneous migraine. *Archives of Neurology* 2005; 62:1270-5

Afridi SK, Kaube H, Goadsby PJ. Occipital activation in glyceryl-trinitrate induced migraine with visual aura. *JNNP* 2005; 76:1158-60

Chapter for "The Headaches- 3rd edition"(Lippincott Williams 2005)

Afridi SK, Shields KG, Bholra R, Goadsby PJ. Greater occipital nerve injection in primary headache syndromes. *Pain* 2006; 122:126-9

Afridi SK, Goadsby PJ. Neuroimaging of migraine. *Current Pain and Headache Reports* 2006;10(3):221-224

Rejdak K, Empl M, Giffin NJ, Afridi SK, Petzold A, Stelmasiak Z, Thompson EJ, Goadsby PJ, Kaube H, Giovannoni G. Increased urinary excretion of nitric oxide metabolites in longitudinally monitored migraine patients. *Eur J Neurol*. 2006 Dec;13(12):1346-51.

Magis D, Bendtsen L, Goadsby PJ, May A, Sánchez del Rio M, Sandór P, Kaube H, Sandrini G, Schoonman G, Schoenen J, Afridi S. Evaluation and proposal for optimization of neurophysiological tests in migraine: Part 2-neuroimaging and the nitroglycerin test. *Cephalalgia* 2007;27 (12): 1339-1359

Afridi S, Giffin N, Kaube N, Goadsby P. A Randomized Controlled Trial of Intranasal Ketamine in Migraine with Prolonged Aura. *Neurology* 2013 12;80(7):642-7

Afridi SK, Holland P. Migraine pathophysiology. *ACNR* 2014, 13(7) 19-21

Mahroo O, Moin D. Mohamed, Graham EM, Mann S, Plant GT, Afridi SK, Hammond CJ. Cilioretinal artery territory infarction associated with papilledema in a patient with Neurofibromatosis Type 2. *Journal of Neuro-Ophthalmology* 2015;0:1–3

Adam Hexter, Adrian Jones, Harry Joe, Miriam J. Smith, Andrew J Wallace, Dorothy Halliday, Allyson Parry, Amy Taylor, Lucy Raymond, Adam Shaw, Shazia Afridi, Rupert Obholzer, Patrick Axon, The English Specialist NF2 Research Group, Jan M. Friedman, D. Gareth R. Evans. Clinical and Molecular Predictors of Mortality in Neurofibromatosis 2: A United Kingdom National Analysis of 1192 Patients

Afridi SK et al. Prevalence and clinical presentation of headache in a National Neurofibromatosis 1 Service and impact on quality of life. *Am J Med Genet A* 2015, 167A(10):2282-5.

Morris, K., Afridi, S., Axon, P., Evans, G., Parry, A., & Halliday, D. (2014). Clinical and Radiological Response of NF2 Associated Tumours to Bevacizumab in an English Cohort (P3. 326). *Neurology*, 82(10 Supplement), P3-326.

Morris, K. A., Golding, J. F., Axon, P. R., Afridi, S., Blesing, C., Ferner, R. E., & McCabe, M. G. (2016). Bevacizumab in Neurofibromatosis type 2 (NF2) related vestibular schwannomas: a nationally coordinated approach to delivery and prospective evaluation. *Neuro-Oncology Practice*, npv065.

Morris KA, Golding JF, Blesing C, Evans DG, Ferner RE, Foweraker K, Halliday D, Jena R, McBain C, McCabe MG, Swampillai A, Warner N, Wilson S, Parry A, Afridi SK UK NF2 research group. Toxicity profile of bevacizumab in the UK Neurofibromatosis type 2 cohort. *J Neurooncol*. 2017 Jan;131(1):117-124

Morris KA, Afridi SK, Evans DG, Hensiek AE, McCabe MG, Kellett M, Halliday D, Pretorius PM, Parry A; , on behalf of the UK NF2 Research Group The response of spinal cord ependymomas to bevacizumab in patients with neurofibromatosis Type 2. *J Neurosurg Spine*. 2017 Apr;26(4):474-482

Ferner RE, Thomas M, Mercer G, Williams V, Leschziner GD, Afridi SK, Golding JF. Evaluation of quality of life in adults with neurofibromatosis 1 (NF1) using the Impact of NF1 on Quality Of Life (INF1-QOL) questionnaire. *Health Qual Life Outcomes*. 2017 Feb 14;15(1):34

Afridi SK, Thomson S, Connor SEJ, Walsh DC, Ferner RE. Aneurysms in neurofibromatosis type 2: Evidence for vasculopathy? *Am J Med Genet A*. 2017 Jun;173(6):1562-1565

Viana M, Afridi S. Migraine with prolonged aura: phenotype and treatment. *Naunyn Schmiedeberg's Arch Pharmacol*. 2018 Jan;391(1):1-7

Afridi SK. Current concepts in migraine and their relevance to pregnancy. *Obstetric Medicine*. April 2018

Lascelles K, Afridi SK, Siddiqui A, Hemingway C, Ganesan V. Cerebral vasculopathy in childhood neurofibromatosis type 2: Cause for concern? *Developmental medicine and child neurology*. May 2018